Physician profile
Mark Silver
NPI 1790869352
$5,302.67
in general payments reported to CMS, 2019-2025
38 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $809 · 2021: $390 · 2022: $665 · 2023: $679 · 2024: $645 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.69 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $717.66 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $419.31 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $394.31 | 2020-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Medtronic, INC. | $347.18 | 2021-2023 | Minimed 780g |
| Lilly USA, LLC | $332.12 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $326.51 | 2019-2024 | |
| Medtronic Minimed, INC. | $321.86 | 2019-2020 | |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Astrazeneca Pharmaceuticals Lp | $238.22 | 2019-2022 | |
| Amgen INC. | $237.02 | 2019-2024 | Tepezza |
| Genzyme Corporation | $185.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $176.59 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $173.46 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $141.27 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.78 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $124.19 | 2019 | |
| Chiasma, INC. | $94.99 | 2021 | |
| Bigfoot Biomedical INC | $60.81 | 2021-2022 | |
| Antares Pharma, INC. | $55.35 | 2022 | |
| Recordati_rare_diseases_inc. | $54.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.02 | 2019 | |
| Ascensia Diabetes Care US INC. | $45.12 | 2021-2023 | |
| Abbott Laboratories | $39.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.00 | 2022 | |
| Esperion Therapeutics, INC. | $28.83 | 2021 | |
| Corcept Therapeutics | $26.79 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $25.41 | 2022 | |
| Abbvie INC. | $23.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.02 | 2023 | Strensiq |
| Vifor Pharma, INC. | $22.98 | 2019 | |
| Eusa Pharma (US) LLC | $22.31 | 2022 | |
| Halozyme INC | $22.11 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $19.50 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $17.61 | 2019 | |
| Lifescan, INC. | $16.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.36 | 2022 | |
| Pfizer INC. | $15.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.